Elan to 'release' $1bn from Tysabri pay-off
This article was originally published in Scrip
Elan will spend $1 billion of the $3.25 billion one-off payment it is receiving from Biogen Idec for the return of rights to the blockbuster multiple sclerosis drug Tysabri to buy back around a 16% stake in the Irish company.
You may also be interested in...
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.